$1.77
-0.18 (-9.23%)
Open$1.90
Previous Close$1.95
Day High$1.90
Day Low$1.71
52W High$80.36
52W Low$1.36
Volume—
Avg Volume26.0K
Market Cap2.60M
P/E Ratio—
EPS$-87.47
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+2,125.4% upside
Current
$1.77
$1.77
Target
$39.39
$39.39
$26.66
$39.39 avg
$54.88
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.03M | 1.06M | 807.5K |
| Net Income | -278,352 | -347,095 | -248,556 |
| Profit Margin | -27.1% | -32.7% | -30.8% |
| EBITDA | -433,012 | -468,823 | -342,942 |
| Free Cash Flow | -135,403 | -181,532 | -119,491 |
| Rev Growth | +14.1% | -2.0% | +8.2% |
| Debt/Equity | 0.22 | 0.23 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |